Please use this identifier to cite or link to this item: http://scholarbank.nus.edu.sg/handle/10635/37568
Title: Therapeutics and drug-designing against infectious diseases using synthetic enzymology
Authors: AISHWARYA.S
Keywords: Infectious diseases, Synthetic enzymology, Suprafamily of enzymes, Orotidine Monophosphate Decarboxylase , Keto gulonate phosphate decarboxylase
Issue Date: 2-Feb-2012
Source: AISHWARYA.S (2012-02-02). Therapeutics and drug-designing against infectious diseases using synthetic enzymology. ScholarBank@NUS Repository.
Abstract: Understanding the emergence of disease and the pathogenesis of multi-drug resistant microorganisms is significant to develop anti-infectives. In this project we endeavored to develop an antimicrobial drug against a Shikimate pathway enzyme, EfaroB and the Plasmodium?s OMPDC enzyme. Initially, EFaroB was expressed, purified and tested for its activity. Nearly 10 enzymes were subsequently chosen to clone, express and purify, to be employed as modifying enzymes for combinatorial biosynthesis. We attempted to decipher the OMPDC-catalyzed mechanism on KGPDC?s scaffold, to understand its mechanism. Mutations were performed on KGPDC orthologues based on the differing key residues between KGPDC and OMPDC enzymes followed by complementation growth studies on the KGPDC mutants. Finally, we tried to chance upon the disparity between the human and Plasmodium?s OMPDCs, for the rational design of an inhibitor against Plasmodium OMPDC, which might have minimal side-effects on the human host, and we noted few distinct key residues as targets.
URI: http://scholarbank.nus.edu.sg/handle/10635/37568
Appears in Collections:Master's Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Development of antiinfectives against infectious diseases_Ash_13.pdf1.81 MBAdobe PDF

OPEN

NoneView/Download

Page view(s)

184
checked on Jan 19, 2018

Download(s)

227
checked on Jan 19, 2018

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.